BELLUS Health Closes US$153 Million Public Offering of Common Shares in Canada and the United States
July 18 2022 - 12:38PM
Business Wire
BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or
“BELLUS Health”) announced today that it has completed its
previously-announced underwritten public offering in Canada and the
United States (the “Offering”) of 16,540,541 common shares at a
price to the public of US$9.25 per common share. The total gross
proceeds to the Company were US$153 million, before deducting the
underwriting commissions and any expenses related to the Offering.
Bellus has also granted to the underwriters an option exercisable
by the underwriters within 30 days of the date of the underwriting
agreement to purchase up to an additional 2,481,081 common shares
of the Company.
BELLUS Health’s common shares are dual-listed on the Nasdaq
Global Market (“Nasdaq”) and the Toronto Stock Exchange (“TSX”)
under the trading symbol “BLU”. For the purposes of the TSX
approval, the Company relied on the exemption set forth in Section
602.1 of the TSX Company Manual, which provides that the TSX will
not apply its standards to certain transactions involving eligible
interlisted issuers on a recognized exchange, such as Nasdaq.
The Company intends to use the net proceeds of the Offering
primarily to fund BLU-5937 research and development activities,
working capital needs and other general corporate purposes, as set
out in the Supplement (as defined below).
Jefferies, Evercore ISI and RBC Capital Markets acted as joint
book-running managers and LifeSci Capital acted as lead
manager.
The Offering was made in Canada pursuant to a prospectus
supplement dated July 13, 2022 (the “Supplement”) to the Company’s
amended and restated short form base shelf prospectus dated
December 14, 2021 (the “A&R Base Prospectus”) and in the United
States pursuant to a registration statement on Form F-10, which
went effective automatically upon its filing with the U.S.
Securities and Exchange Commission (the “SEC”) on December 14, 2021
(the “Registration Statement”), containing the Supplement and
A&R Base Prospectus filed with the SEC in accordance with the
Multijurisdictional Disclosure System established between Canada
and the United States.
The Supplement and the accompanying A&R Base Prospectus
contain important detailed information about the Offering. The
Supplement and the accompanying A&R Base Prospectus can be
found on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Copies
of the Supplement and accompanying A&R Base Prospectus may also
be obtained from the Company, by telephone at 450-680-4500 or by
email at info@bellushealth.com or you may request them from, in the
United States, Jefferies LLC, Attention: Equity Syndicate
Prospectus Department, 520 Madison Avenue, New York, NY 10022, by
telephone at 877-821-7388 or by email at
prospectus_department@jefferies.com, or Evercore Group L.L.C.,
Attention: Equity Capital Markets , 55 East 52nd Street, 35th
Floor, New York, NY 10055, by telephone at 888-474-0200 or by email
at ecm.prospectus@evercore.com, or RBC Capital Markets, LLC,
Attention: Equity Capital Markets, 200 Vesey Street, 8th Floor, New
York, NY 10281, by telephone at 877-822-4089 or by email at
equityprospectus@rbccm.com or, in Canada, Jefferies Securities,
Inc., Attention: General Counsel, 161 Bay Street, Suite 2600,
Toronto, ON M5J 2S1 by email at
prospectus_department@jefferies.com, or RBC Dominion Securities
Inc., Attention: Distribution Centre, 180 Wellington Street West,
8th Floor, Toronto, ON M5J 0C2, by telephone at 1-416-842-5349 or
by email at Distribution.RBCDS@rbccm.com. Prospective investors
should read the Supplement and accompanying A&R Base Shelf
Prospectus and the other documents the Company has filed before
making an investment decision.
No regulatory authority has either approved or disapproved the
contents of this news release. This news release shall not
constitute an offer to sell or the solicitation of an offer to buy,
nor shall there be any sale of these securities in any province,
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to the registration or qualification under
the securities laws of any such province, state or
jurisdiction.
About BELLUS Health
BELLUS Health Inc. is a clinical-stage biopharmaceutical company
developing novel therapeutics for the treatment of refractory
chronic cough (“RCC”) and other hypersensitization-related
disorders. The Company's product candidate, BLU-5937, is being
developed for the treatment of adults with RCC.
Cautionary Note Regarding Forward-Looking Statements
Certain statements contained in this news release, other than
statements of fact that are independently verifiable at the date
hereof, may constitute "forward-looking statements" within the
meaning of Canadian securities legislation and regulations, the
U.S. Private Securities Litigation Reform Act of 1995, as amended,
and other applicable securities laws. Such statements, based as
they are on the current expectations of management, inherently
involve numerous important risks, uncertainties and assumptions,
known and unknown. In this news release, such forward-looking
statements include, but are not limited to, the anticipated use of
proceeds from the Offering. Actual future events may differ from
the anticipated events expressed in such forward-looking
statements. BELLUS Health believes that expectations represented by
forward-looking statements are reasonable, yet there can be no
assurance that such expectations will prove to be correct. The
reader should not place undue reliance, if any, on any
forward-looking statements included in this news release. These
forward-looking statements speak only as of the date made, and
BELLUS Health is under no obligation and disavows any intention to
update publicly or revise such statements as a result of any new
information, future event, circumstances or otherwise, unless
required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220716005008/en/
Investors: Ramzi Benamar Chief Financial Officer
rbenamar@bellushealth.com
Media: Julia Deutsch Solebury Trout
jdeutsch@soleburytrout.com
BELLUS Health (NASDAQ:BLU)
Historical Stock Chart
From Apr 2024 to May 2024
BELLUS Health (NASDAQ:BLU)
Historical Stock Chart
From May 2023 to May 2024